Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuriaopen access
- Authors
- Piao, Xuan-Mei; Jeong, Pildu; Kim, Ye-Hwan; Byun, Young Joon; Xu, Yanjie; Kang, Ho Won; Ha, Yun-Sok; Kim, Won Tae; Lee, Jong-Young; Woo, Seung Hwo; Kwon, Tae Gyun; Kim, Isaac Y.; Moon, Sung-Kwon; Choi, Yung Hyun; Cha, Eun-Jong; Yun, Seok Joong; Kim, Wun-Jae
- Issue Date
- Jan-2019
- Publisher
- WILEY
- Keywords
- noninvasive biomarker; miRNA; bladder cancer; hematuria
- Citation
- INTERNATIONAL JOURNAL OF CANCER, v.144, no.2, pp 380 - 388
- Pages
- 9
- Journal Title
- INTERNATIONAL JOURNAL OF CANCER
- Volume
- 144
- Number
- 2
- Start Page
- 380
- End Page
- 388
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/18320
- DOI
- 10.1002/ijc.31849
- ISSN
- 0020-7136
1097-0215
- Abstract
- The most common symptom of bladder cancer (BC) is hematuria. However, not all patients with hematuria are diagnosed with BC. Here, we explored a novel method to discriminate BC from hematuria under nonmalignant conditions by measuring differences in urinary cell-free microRNA (miRNA) expression between patients with BC and those with hematuria. A multicenter study was performed using 543 urine samples obtained from the National Biobank of Korea, including 326 BC, 174 hematuria and 43 pyuria without cancer. The urinary miR-6124 to miR-4511 ratio was considerably higher in BC than in hematuria or pyuria, and enabled the discrimination of BC from patients with hematuria at a sensitivity of >90% (p < 0.001). Conclusively, the proposed noninvasive diagnostic tool based on the expression ratio of urinary cell-free miR-6124 to miR-4511 can reduce unnecessary cystoscopies in patients with hematuria undergoing evaluation for BC, with a minimal loss in sensitivity for detecting cancer.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.